Heron Therapeutics is trading at $0.38, up 7.31%, and available sources do not establish a direct cause for the October 9 gain.
- No company-specific announcement explaining the move was identified; Heron’s news page lists its August 10 second-quarter results as the latest release.
- XBI rose 2.50% during the regular session, offering sector context but not evidence of a Heron-specific catalyst.
- Shares closed at $0.36 on October 8, according to the supplied price context.